Healthy volunteers help test first doses of experimental drug KT-621
NCT ID NCT06673667
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This early-stage study tested the safety of a new oral drug, KT-621, in 118 healthy adults aged 19 to 55. Participants received either the drug or a placebo to check for side effects and how the drug moves through the body. The goal was not to treat any disease, but to gather essential safety information for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS STUDY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion
Phoenix, Arizona, 85283, United States
-
Celerion
Lincoln, Nebraska, 68502, United States
Conditions
Explore the condition pages connected to this study.